KaliVir Immunotherapeutics is a privately held biotech company developing cutting-edge, next-generation oncolytic viral immunotherapy programs. The company has developed a unique vaccinia virus-based platform that can generate potent novel oncolytic vaccinia viruses with modifications to maximize viral replication and to enhance intravenous delivery and spread (Vaccinia Enhanced Template "VET" Platform). VET Platform utilizes the large transgene capacity of the vaccinia virus to deliver therapeutics matched to tumor immunophenotypes to stimulate patients' immune systems and modify the tumor microenvironment. KaliVir's oncolytic product candidates are designed to be safe, potent and systemically deliverable to treat cancer patients across multiple tumor types. KaliVir and Astellas Pharma are developing KaliVir's VET2-L2 oncolytic virus for immuno-oncology through a worldwide licensing agreement. Simultaneously, KaliVir is in the process of advancing multiple therapeutic candidates toward the clinic. For more information, please visit www.kalivir.com.